Virax Biolabs Closes Exercise of Preferred Investment Options for $3.3 Million
Virax Biolabs Group Limited announced it has closed the previously announced exercise of preferred investment options, generating approximately $3.3 million in gross proceeds before fees and expenses. The transaction involved the purchase of up to 548,000 ordinary shares at a reduced price.
Topics: capital raising preferred investment options share issuance